GSK · story · 7 November
GSK · 6 headlines from 6 outlets, on 7 November 2026.
GSK and Moderna settled their COVID and RSV vaccine patent fight without payments.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Bilyonaryo Business is the largest at 7.5, ahead of Traders Union (7.5). Tech Times is the smallest at 4.2.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Bilyonaryo Business | 7.5 |
| Traders Union | 7.5 |
| Reuters | 7.3 |
| Euronext Markets: Real-time Stock Market Data | live | 7.3 |
| Law360 | 7.0 |
| Tech Times | 4.2 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Bilyonaryo Business | 1 | +7.5 |
| Traders Union | 1 | +7.5 |
| Reuters | 1 | +7.3 |
| Euronext Markets: Real-time Stock Market Data | live | 1 | +7.3 |
| Law360 | 1 | +7.0 |
| Tech Times | 1 | +4.2 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +7.5 | Removes a patent dispute with no payments required |
| +7.5 | Settlement covers both US and European disputes |
| +7.3 | Major legal overhang settled across COVID and RSV products |
| +7.3 | Repeat of the settlement news from a market data site |
| +7.0 | Litigation in Delaware brought to a close |
| +4.2 | Mainly about Moderna's results; GSK dispute resolution is a side benefit |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.